PIONEER-PEDS2-H8H-MC-LAHW(b): A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine

Grants and Contracts Details

StatusActive
Effective start/end date3/2/221/24/25

Funding

  • Eli Lilly and Company: $19,291.00